[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100419745":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":42,"locations":50,"responsibleParty":70,"collaborators":26,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":26,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":26,"overallStatus":52,"whyStopped":26,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"cyclophosphamide and prednisone","ACTIVE_COMPARATOR","Prednisone will be given at 1mg\u002Fkg\u002Fd p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.\n\nCyclophosphamide will be given at 1-2mg\u002Fkg\u002Fd p.o. with a target accumulated dose of 12g.\n\nAzathioprine or mycophenolate mofetil are optional which could be given for a short period of time (\\\u003C6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month.",[13,14],"Drug: Prednisone","Drug: Cyclophosphamide",{"label":16,"type":10,"description":17,"interventionNames":18},"Rituximab","Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count\\>5\u002Ful on the 15th day.\n\nCalcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months.",[19],"Drug: Rituximab",[21,27,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Prednisone","1mg\u002Fkg\u002Fd p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Cyclophosphamide","1-2mg\u002Fkg\u002Fd p.o. with a target accumulated dose of 12g.",[9],[32],"CTX",{"type":22,"name":16,"description":34,"armGroupLabels":35,"otherNames":36},"1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\\>5\u002Ful.",[16],[37],"CD20 antibody",[39],{"name":40,"affiliation":5,"role":41},"Yan Qin","PRINCIPAL_INVESTIGATOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Sanxi Ai","CONTACT","18811054896","sanxiai@163.com",{"name":40,"role":45,"phone":26,"phoneExt":26,"email":49},"qinyanbeijing@126.com",[51],{"facility":5,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":59,"coordinates":60},"Point",[61,62],116.39723,39.9075,{"lat":62,"lon":61},[65,66,67,68],{"name":44,"role":45,"phone":26,"phoneExt":26,"email":47},{"name":40,"role":45,"phone":26,"phoneExt":26,"email":49},{"name":40,"role":41,"phone":26,"phoneExt":26,"email":26},{"name":69,"role":41,"phone":26,"phoneExt":26,"email":26},"Qi Miao",{"type":71,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100419745","phase-3-different-immunosuppressive-treatment-in-imn-100419745",false,"NCT04745728","Different Immunosuppressive Treatment in iMN","Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort","Inclusion Criteria:\n\n* idiopathic membranous nephropathy\n* Female, must be post-menopausal, sterile or have effective contraception\n* must be off steroid or mycophenolate mofetil for \\>1 month and alkylating agents for or RTX\\> 6 months\n* Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive therapy or if patients are intolerant to ACEI\u002FARB.\n* proteinuria ≥4g\u002F24h and decreased ≤ 50% from baseline\n\nExclusion Criteria:\n\n* presence of active infection or a secondary cause of membranous nephropathy\n* proteinuria associated with diabetic nephropathy\n* pregnancy or breast feeding\n* history of resistance to rituximab or alkylating agents or corticosteroid\n* Patients who previously achieved remission after treatment of rituximab or alkylating agents but relapsed off rituximab or alkylating agents after 6 months are eligible.","ALL","18 Years","80 Years",{"count":83,"type":84},200,"ESTIMATED","INTERVENTIONAL",[87],"PHASE3","The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)",[90],"Idiopathic Membranous Nephropathy","2025-12-02",{"date":93,"type":94},"2025-12-09","ACTUAL",{"date":96,"type":94},"2021-04-14",{"date":98,"type":84},"2029-12",{"name":5,"class":6},1]